On Nov 05, major Wall Street analysts update their ratings for $Verona Pharma (VRNA.US)$, with price targets ranging from $42 to $64.
Wells Fargo analyst Tiago Fauth maintains with a buy rating, and maintains the target price at $64.
Jefferies analyst Andrew Tsai maintains with a buy rating, and adjusts the target price from $38 to $45.
BTIG analyst Thomas Shrader maintains with a buy rating, and adjusts the target price from $34 to $51.
Truist Financial analyst Joon Lee maintains with a buy rating.
CCORF analyst Edward Nash maintains with a buy rating, and adjusts the target price from $37 to $44.
Furthermore, according to the comprehensive report, the opinions of $Verona Pharma (VRNA.US)$'s main analysts recently are as follows:
The company's sales in October were reported to surpass those in Q3, even before the acquisition of a permanent J-code and the potential inclusion in the GOLD guidelines. This not only indicates a promising near-term launch trajectory but also substantially lessens the risk of a launch 'fizzle'.
Verona Pharma's Q3 sales outperformed expectations, with a reported $5.6M surpassing the projected $2M. This performance, coupled with a novel mechanism of action, management's optimistic outlook for Q4 and beyond into 2025, and favorable evaluations, leads to the anticipation of increased sales momentum. This bolsters the prospects for what could become a leading COPD treatment.
Here are the latest investment ratings and price targets for $Verona Pharma (VRNA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
